Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay

Muley, Thomas; Ébert, W.; Stieber, P.; Raith, Hannelore; Holdenrieder, Stefan; Nagel, Dorothea; Fürst, H.; Roth, Hans-Jürgen; Luthe, Hilmar; Blijenberg, B. G.; Gurr, Eberhard; Uhl, Wolfgang; Pawel, Joachim von; Drings, P.

doi:10.1515/cclm.2003.017

Cited by 28 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NSE (9 ) has been found to increase after brain injury, such as stroke (10,11 ), but it is also increased in cancers of neuroendocrine origin, such as small-cell lung cancer, neurobastoma, carcinoid tumors, and melanoma (12 ). In addition, hemolysis has been reported to cause positive interference in at least one of the commercially available procedures for its measurement (13 ).…”

mentioning

confidence: 99%

Identification of Novel Brain Biomarkers

Modur²,

et al. 2006

View full text Add to dashboard Cite

Background:The diagnosis of diseases leading to brain injury, such as stroke, Alzheimer disease, and Parkinson disease, can often be problematic. In this study, we pursued the discovery of biomarkers that might be specific and sensitive to brain injury. Methods: We performed gene array analyses on a mouse model to look for biomarkers that are both preferentially and abundantly produced in the brain. Via bioinformatics databases, we identified the human homologs of genes that appeared abundant in brain but not in other tissues. We then confirmed protein production of the genes via Western blot of various tissue homogenates and assayed for one of the markers, visinin-like protein 1 (VLP-1), in plasma from patients after ischemic stroke. Results: Twenty-nine genes that were preferentially and abundantly expressed in the mouse brain were identified; of these 29 genes, 26 had human homologs. We focused on 17 of these genes and their protein products on the basis of their molecular characteristics, novelty, and/or availability of antibodies. Western blot showed strong signals in brain homogenates for 13 of these proteins. Tissue specificity was tested by Western blot on a human tissue array, and a sensitive and quantitative sandwich immunoassay was developed for the most abundant gene product observed in our search, VLP-1. VLP-1 was detected in plasma of patients after stroke and in cerebrospinal fluid of a rat model of stroke. Conclusions: The use of relative mRNA production appears to be a valid method of identifying possible biomarkers of tissue injury. The tissue specificity suggested by gene expression was confirmed by Western

show abstract

mentioning

confidence: 99%

Identification of Novel Brain Biomarkers

Modur²,

et al. 2006

View full text Add to dashboard Cite

show abstract

“…However, this method presents some advantages with respect to other ELISA methods. The ELECSYS has a low intraand interassay coefficient of variation (0.7%-5.3%), reportable range between 0.0 and 320 ng/mL and a short incubation time of 18 min (24). In addition, in the study by Wunderlich et al (19), the concentrations of NSE assessed with the LIAISON kit (DiaSorin, Diagnostica, Dietenzbach, Germany) exceeded the cut-off value of 12.5 ng/mL in 13% of stroke patients only, during the first 24 h.…”

Section: Discussionmentioning

confidence: 99%

Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke

Brea

Sobrino

Blanco

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Background: Neuron-specific enolase (NSE) and S100 protein are implicated in several brain injuries, including stroke. Our objective was to analyze the temporal profile and the clinical significance of NSE and S-100 in acute ischemic (IS) and intracerebral hemorrhage (ICH). Methods: We studied 224 patients with IS and 44 patients with ICH. Computerized tomography (CT) scans were performed to assess infarct volume. Stroke severity was evaluated using the National Institute of Health Stroke Scale (NIHSS), and functional outcome at 3 months with the modified Rankin Scale (mRS). Serum NSE and S100 protein were measured using an electrochemiluminescenceimmunoassay. Results: Peak values were found at 72 h for NSE and at 24 h for S100 in IS. For ICH, peak values were found at 24 h for both NSE and S100. At these time intervals S100 and NSE correlated with the NIHSS score and were independently associated with poor outcome. Conclusions: High serum NSE and S100 are associated with poor outcome in IS, and high serum NSE is associated with poor outcome in ICH. These findings suggest the potential utility of NSE and S100 as prognostic markers for acute stroke. Clin Chem Lab Med 2009;47:1513-8.

show abstract

“…16 NSE was shown to be increased in cerebrospinal fluid and blood as a result of injury due to reasons, such as cardiac arrest, open heart surgery, tonicclonic seizures, epilepsy, and Creutzfeldt-Jakob disease. 17 In addition to that, in the liver diseases, erythrocytes, and benign lung tumor; the concentration of NSE increased (grow up to 20 μg L -1 ).…”

Section: Introductionmentioning

confidence: 94%

“…17 NSE is considered as a marker of many diseases such as brain damage (traumatic brain injury), stroke and anoxic encephalopathy after cardiac arrest. Generally, in adults NSE accepted as a marker protein in the brain.…”

Section: Introductionmentioning

confidence: 99%

Relationship of Serotonin to Neuron Specific Enolase In Serum Samples of Patients with Advanced Stages of Cancer Tumors

Matlab¹,

Jasim²

2017

ECB

View full text Add to dashboard Cite

Cancer is heterogeneous disorders characterized by cellular different genetic alterations and diverse clinical behaviours results from uncontrolled division leads to loss of control of the cells growth. Neuron Specific Enolase(NSE) is considered as a marker of many diseases such as brain damage (traumatic brain injury), stroke and anoxic encephalopathy after cardiac arrest. Generally, in adults NSE accepted as a marker protein in the brain. Serotonin exhibits a growth stimulatory effect on several types of carcinoma, carcinoid and other tumor cells. In contrast, a few data are available on serotonin involvement in cancer cell migration and metastatic processes. Serum serotonin level was found to be suitable for prognosis evaluation of urothelial carcinoma in the urinary bladder, adenocarcinoma of the prostate and renal cell carcinoma. 201 patients with malignant tumors, 74 patients with different benign tumors and, 83 healthy individuals were enrolled in the present study. Our results show a significant increase (p = 0.011, and 0.043) of serum serotonin levels in malignant tumors group when compared with those of benign tumors (as a pathological control) group, and healthy individuals groups; respectively. No such results were shown when the two control (benign tumors and healthy individuals) groups were compared together. While evaluation of the NSE concentrations revealed a significant decrease in patients with malignant tumors when compared with those of benign tumors (p = 0.028), and healthy individuals (p< 0.000). According to ANOVA test, Same variations (p < 0.000) were obtained when benign tumors and healthy controls groups were compared together. Results shows a significant decrease in the serotonin concentration (p < 0.05) as well as the NSE (p < 0.01) levels, correlation between the levels of the two examined parameters has been negative and statically acceptable (r = -0.723 at p<0.05) at malignant tumor patients group after treatment by chemotherapy or radiotherapy. Before treatment with chemotherapy or radiotherapy, negatively significant correlation (r = -0.792 at p < 0.001) was observed for the concentrations of Serotonin to the NSE in the sera of malignant tumor patients group, while no such correlations were noted at this relation examined in the benign tumor patients. Serotonin and NSE correlations together can be used as primary diagnostic tools for distinguishing between cancerous and benign tumors, this correlation increases the sensitivity of the two biomarkers together comparing to measure everyone alone. * Corresponding Authors

show abstract

Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay

Cited by 28 publications

References 30 publications

Identification of Novel Brain Biomarkers

Identification of Novel Brain Biomarkers

Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke

Relationship of Serotonin to Neuron Specific Enolase In Serum Samples of Patients with Advanced Stages of Cancer Tumors

Contact Info

Product

Resources

About